Value through Innovation04 March 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance at EASD Annual Meeting

- EX US & UK Medical Media Only

Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis

- For NON-U.S Health Media Only

CHMP recommends indication for the use of Trajenta® (linagliptin) tablets as add-on therapy to insulin in adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media

Boehringer Ingelheim submits first oncology compound, afatinib* for European approval

- For NON-US media only

Boehringer Ingelheim launches beta social game Syrum to promote science and innovation

- For Non-US and Non-Canadian Media Only

Asian populations with atrial fibrillation (AF) benefit from better stroke prevention with Pradaxa® (dabigatran etexilate) compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim implements flexible fully disposable up- and downstream manufacturing for biopharmaceuticals


Boehringer Ingelheim and the ETH Zurich announce diabetes and obesity research collaboration


SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD

- For medical media outside the USA and UK

New data show significant improvements in lung function using combination of tiotropium and olodaterol* in COPD patients

- For Media outside the U.S. and UK

Phase III results: tiotropium* Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment

- For Media outside the U.S. and UK

New bottle for Ingelvac MycoFLEX® simplifies mixing with Ingelvac CircoFLEX®


Large scale registry shows atrial fibrillation management is suboptimal and unequal around the world

- For Non-US, Non-UK & Non-Canadian Media Only

Key results from new tiotropium studies in COPD and asthma
to be presented at ERS 2012

- For Media outside the U.S. and UK

Clinical experience with Pradaxa® crosses one million patient-years of treatment

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim achieves further growth in first half of 2012 – difficult business environment expected for the second half of the year


Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier


Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media